-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of August 31, a total of 485 A-share companies had issued earnings forecasts for the third quarter of 2020, according to statistics from Pharmaceutical Network Industry Dynamics.
of the 485 companies, 105, or 21.6 per cent, had pre-increased third-quarter results, and net profit of at least 30 per cent had increased by more than 100 per cent.
in terms of industry, the biopharmaceutical sector is more prominent.
, for example, on August 9th, Sanxiang Bio issued a earnings forecast, forecasting a net profit attributable to shareholders of listed companies of 1.737 billion to 9224.12% YoY for the Period January-September 2020.
the medical device services industry grew by an average of -1.17%.
company made the above forecast for the following reasons: mainly due to the large contribution of sales of testing reagents and the substantial increase in sales revenue of testing instruments.
data show that the company is an independent innovation of gene technology as the core, set diagnostic reagents and instruments research and development, production, sales, as well as third-party medical testing services in one of the overall in-body diagnostic solutions provider.
the first half of 2020, the net profit attributable to shareholders of listed companies was RMB778 million, an increase of 11.9 times over the same period a year earlier (a change of 1186.48%).
also disclosed its third-quarter earnings forecast, expecting net profit of 1.1 billion yuan to 1.4 billion yuan in the first three quarters of this year, up 1272.06 percent to 1646.26 percent from a year earlier.
reasons for the change in performance, the company explained that the impact of the outbreak, the market demand for nucleic acid testing reagents increased significantly.
company is a high-tech biopharmaceutical enterprises based on Zhongshan University, led by molecular diagnosis, set clinical testing reagents and instruments for research and development, production and sales.
the evening of August 25, Blue Fan Medical released its 2020 half-yearly report, reporting a net profit attributable to shareholders of listed companies of 621 million yuan in the first half of the year, up 164.85 percent year-on-year.
expects net profit attributable to shareholders of listed companies to be 1.800 billion to 2.100 billion yuan in the January-September period, up 380.00% to 460.00% YoY, with an average net profit growth rate of 125.87 percent in the medical device services industry.
said that medical and protective products, including medical and protective gloves, all kinds of masks and other demand has increased, the sales structure has been further optimized, sales prices have increased, the company's performance has a positive impact.
company is a medical device company mainly producing medical and protective gloves, but also the domestic health protection gloves industry's top listed company.
, some Chinese medicine companies in the first three quarters of the performance is not bad.
For example, on the evening of August 27th, Chinese medicine head enterprises disclosed the 2020 half-yearly report, and in the first half of the year, the company realized a net profit attributable to shareholders of listed companies of 714 million yuan, up 57.05 percent year-on-year, more than the whole of the previous year.
same time, Erling Pharmaceuticals forecast its first three-quarter results, which are expected to reach 977 million yuan to 1.035 billion yuan, up 70%-80% year-on-year.
industry believes that the new model of academic innovation and transformation of Chinese medicine, which has been carried out by Ering Pharmaceuticals for many years, has become the cornerstone of its performance growth.
enterprises in the first two quarters of the single-quarter net profit growth rate of 52%, 66%, the third quarter profit is expected to exceed 120%, showing a quarter-by-quarter accelerated trend, bright performance exceeded market expectations.
On the evening of August 24th, Sassoko Pharmaceuticals, which specialty medicinal fungi products, Chinese medicine tablets and Chinese medicine formula particles, also released its third-quarter 2020 earnings forecast, forecasting a profit of 58.5 million yuan to 61.5 million yuan in the first three quarters of this year, up 51.17% to 58.93% YoY.
's semi-annual report, the company achieved a net profit attributable to shareholders of listed companies of 30.7061 million yuan in the first half of 2020, up 11.61 percent from a year earlier.
In the performance change statement, Zoellick Pharmaceuticals pointed out that the company actively faced changes in the external environment, seize the implementation of the national basic drug policy, medical insurance catalog adjustment, classification of patient sinking, Internet diagnosis and treatment and the introduction of long-term prescription policy for chronic diseases and other development opportunities, with the core products Wuling capsules, hundred tablets, Lingze tablets into the national basic drug catalog advantages, self-employment, strong investment, increase market input and end-of-life medical institutions development and coverage.